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Summary
Background: A study to evaluate the adherence to and appropriateness of anti-osteoporotic treatments in a
cohort of men and women aged 50 and over participating in the ESOSVAL-R study.
Methods/Design: Design: An observational, longitudinal, prospective cohort study; Study subjects: Men and
women aged 50 and over living in the Valencia Region (Spain) who initiated treatment between June 15, 2009,
and June 15, 2011, in primary healthcare centers with electronic medical records; Data sources: The main data
source will be electronic medical records. Measurement of results: Degree of compliance with and persistence of
anti-osteoporotic treatments, and the proportion of patients with appropriate anti-osteoporotic treatment in
accordance with the most relevant and high impact recommendations with clearly defined treatment algorithms
in Spain (the Spanish National Health System guide (2010), the General Practitioners’ Society (2007) and the
General Directorate for Pharmacy and Medical Products of Madrid (2007)), and with the National Osteoporosis
Foundation (NOF, 2010), and the International Osteoporosis Foundation guidelines (IOF, 2008); Analysis: 1.)
Descriptive analysis of patients undergoing treatment and the treatments prescribed; 2.) Descriptive analysis of
compliance with and persistence of anti-osteoporotic treatments; 3.) Analysis of factors associated with compliance
with and persistence of treatments by Cox proportional hazard regression models, 4.) Descriptive analysis of
appropriateness of treatment; 5.) Analysis of factors associated with the appropriateness of treatment by multilevel
models (4 levels: patient, doctor, Basic Healthcare Zone/Primary Healthcare Center, and Health Area variables).
Discussion: ESOSVAL-AD will provide information regarding adherence to osteoporosis treatments and the factors
associated with a higher or lower adherence (including the appropriateness of the treatment) in the Spanish
context. A better understanding of this phenomenon and the interventions needed to address it would contribute
to the increased effectiveness of therapeutic measures, a reduction in morbidity and mortality, and a
corresponding reduction in healthcare costs.
Background
Osteoporotic fractures constitute a serious health pro-
blem not only because of their severe consequences for
patients in terms of pain and l i m i t e df u n c t i o n ,b u ta l s o
because of their important social and economic reper-
cussions. Although many issues remain to be clarified
[1], numerous studies have associated osteoporotic frac-
tures (hip and also vertebral fractures) with higher mor-
tality rates [2-4].
Osteoporosis is thus a high priority health problem.
Paradoxically, although effective, well-tolerated treatments
for managing this condition through fracture risk reduc-
tion are available in Spain, the Clinical Practice Guidelines
(CPGs) of the various scientific societies that focus on this
health problem (SEMFYC, SEMI, SER, SEMERGEN,
SEIOMM, SECOT) give no recommendations for deciding
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ity estimates. The proposal made by Vázquez et al. (2007)
[5] is the only one that establishes treatment thresholds
based on 10-year fracture risk estimates, both for vertebral
and hip fractures.
Internationally, the most relevant and influential risk
scale is that developed by the World Health Organiza-
tion (FRAX). This scale estimates the risk of major
osteoporotic fractures (vertebrae, hip, wrist, or humerus)
as well as of hip fractures alone. Based on this scale,
Kanis [6] and Dawson-Hughes [7] (IOF/NOF) have pro-
posed intervention thresholds for the UK and the US
for establishing treatment for major osteoporotic frac-
tures as well as vertebral fractures and these have been
included in the NOF recommendations. Recently, Hip-
pisley-Cox (2009) [8] proposed an algorithm validated in
the English population for estimating the individual 10-
year risk for osteoporotic fractures (vertebrae, hip, or
wrist) and hip fractures which predicts fracture risk
without the need for complementary examinations.
The current situation, which combines scarce estima-
tions of fracture risk with uncertainty and controversy
concerning treatment candidates, has led to wide varia-
bility in the therapeutic management of osteoporosis.
This variability encompasses undertreatment in high
fracture risk patients as well as overtreatment in patients
with a low fracture risk. With regard to the latter, a
recent study carried out in a primary healthcare center
in Madrid [9] found that 48% of patients treated with
antiresorptive drugs did not meet the criteria for receiv-
ing treatment as set out in the CPGs most frequently
used in Spain (developed by the scientific societies of
various specialties: SER, SEIOMM, SEMFyC, SEMI,
SECOT, SEMERGEN).
Along with this problem of the inappropriateness of
treatment (including both under and overuse of certain
drugs), treatments effectiveness for chronic diseases has
the added difficulty of a patient’s adherence to that treat-
ment. Because response to treatment is related to both
the dose and the administration regimen of drugs, non-
compliance with treatment may reduce its benefits [10]
and may also reduce its effectiveness [11,12]. Neverthe-
less, a low level of compliance with medical prescriptions
is quite prevalent. Although a global quantification of
non-compliance is difficult due to its variations depend-
ing on the disease and also with regard to the different
therapeutic indications, it is estimated to reach 50% for
therapeutic indications in chronic diseases [13].
Few studies have analyzed the adherence to treatments
involving antiresorptive drugs. A recent systematic
review of the literature [14] found an adherence rate of
67% for the first year of treatment, with an average per-
sistence of 180 days of treatment/year (the review did
not include any studies carried out in Spain). The few
Spanish studies that have been published to date show
similar or slightly lower compliance rates; however, they
are difficult to assess as they included interventions to
improve compliance. With respect to associated treat-
ments, one recent study carried out in Spain estimated
that compliance with taking calcium and/or vitamin D
supplements was around 50% [15]. In contrast, a study
conducted in our setting with regard to Hormone
Replacement Therapy (prior to the publication of the
WHI clinical trial), estimated that there was a 75% prob-
ability that the women in the study would comply with
the therapy for 5 years [16].
The lack of studies in this field contrasts with the high
relevance of knowing the rate of adherence to osteo-
porosis treatments and the factors associated with a
higher or lower adherence (including the appropriate-
ness of the treatment) in each specific context. This is
indeed a relevant research aim given that a better
understanding of this phenomenon and the interven-
tions needed to address it could contribute to the
increased effectiveness of therapeutic measures, a reduc-
tion in morbidity and mortality, and a corresponding
reduction in healthcare costs [17].
In our setting an observational, prospective cohort
study (the ESOSVAL-R study) is currently being carried
out, in which 14,500 men and women will be followed-
up for 5-10 years with the collaboration of 800 health
care professionals from the Valencia Health Agency. Its
objective is to develop a predictive risk scale for osteo-
porotic fractures for the adult population of the Valen-
cia Region, to evaluate its validity, and to generate the
information necessary for defining treatment criteria
based on the fracture risk [18].
Within this cohort, which will be followed-up primar-
ily with the aid of data from the electronic medical
records system (ABUCASIS), which has just been rede-
signed, as well as from the electronic prescription sys-
tem (GAIA), it will be possible to nest a second
prospective cohort made up of patients who have
recently begun treatment for osteoporosis. This cohort
will be followed up to evaluate the adherence to and
appropriateness of treatments as well as to analyze the
factors associated with adherence. The aim of the pre-
sent research project (ESOSVAL ADherence/Appropri-
ateness or ESOSVAL-AD) is to evaluate the adherence
(compliance and persistence) to and the appropriateness
of anti-osteoporotic treatments in a cohort (nested
within the ESOSVAL-R cohort) of patients who initiated
these treatments within 2009 and 2010.
Methods/Design
Main Objective
To describe the adherence to and appropriateness of the
indications of anti-osteoporotic treatments in a cohort
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anti-osteoporotic treatment in 2009-2010 and who were
included in the ESOSVAL-R cohort; and to analyze the
relationships between adherence and appropriateness as
well as between fracture risk and adherence and
appropriateness.
Specific objectives
1. To describe the sociodemographic and clinical char-
acteristics of the cohort.
2. To describe the treatments administered stratifying
by age, sex, and certain clinical characteristics (presence
of vertebral fracture, comorbidity, polypharmacy, frac-
ture risk).
3. To evaluate the adherence (compliance and persis-
tence) to anti-osteoporotic treatment in global terms as
well as specifically for appropriate and inappropriate
indications.
4. To evaluate the appropriateness of the anti-osteo-
porotic treatments.
5. To analyze the factors (patient, professional, organi-
zational) associated with treatment appropriateness
using multilevel models.
6. To analyze the factors associated with persistence
and compliance with anti-osteoporotic therapies using
proportional risk regression models.
Design
This is an observational, longitudinal, prospective cohort
study with a minimum follow-up period of two years.
T h ed a t au s e di nt h es t u d yw i l lb eo b t a i n e dp r i m a r i l y
from the electronic clinical records system (ABUCASIS),
specifically from the electronic prescription system
(GAIA) and the ESOSVAL module which was designed
for the management and follow-up of osteoporotic
patients. To evaluate persistence with anti-osteoporotic
treatment, patients will be followed up from the time of
their inclusion in the study until June 15, 2013.
Setting
The sample will be recruited from the Valencia Region,
Spain (Primary Care practices of the Valencia Health
Agency whose professionals are participating in the
ESOSVAL-R project. This includes 450 practices and
800 healthcare professionals.)
Population and sample
The characteristics of the ESOSVAL cohort have been
amply described elsewhere [18]. In brief, the cohort
comprises 14,500 men and women aged 50 and over
who live in the Valencia Region and who were recruited
opportunistically from among the patients who attended
the collaborating primary care centers. Excluded from
the study were those patients with cognitive
impairments, those not insured through the Valencia
Health Agency (e.g. members of civil servant insurance
mutuals), people who are physically unable to attend
their usual primary healthcare center, non-residents of
the Valencia Region, and people of Asian or African
descent. From the selected study population, a smaller
nested cohort (ESOSVAL-AD) was chosen to include
patients who had initiated anti-osteoporotic treatment
in the 12 months prior to or after their inclusion in the
general cohort (between June 15, 2009, and June 15,
2011). In order to make the study population more
homogeneous by avoiding the inclusion (as initial cases)
of treated patients who had discontinued treatment dur-
ing any given month, patients who had received anti-
osteoporotic treatment in the 6 months prior to being
selected were excluded from the ESOSVAL-AD cohort.
Estimates indicated the possibility of obtaining an n of
approximately 500 subjects who had initiated treatment
in the ESOSVAL-AD inclusion period, which is some-
what higher than the 330 required to estimate the main
endpoint of the study with a precision of ± 5 (alpha:
0.05, power: 0.80), but useful for improving the power
of the secondary analyses.
Outcomes
Main endpoint
Extent of compliance with the anti-osteoporotic treat-
ment prescribed, calculated as the number of pills dis-
pensed in relation to the number of pills necessary for
treatment during the time period evaluated. Good com-
pliance is when a patient has picked up more than 80%
of the prescribed drug from the pharmacy during the
corresponding follow-up period.
Secondary endpoints
1) Persistence of medication is defined as the time
elapsed between the start of a given treatment and its
interruption [19]. With regard to this variable, treatment
starts when a patient receives a prescription for a given
anti-osteoporotic drug, always when the patient has not
received any other prescriptions for anti-osteoporotic
drugs in the previous 6 months. Treatment ends when
the patient has not received the prescribed anti-osteo-
porotic drug for three months (90 days time lag). 2)
Proportion of patients with appropriate anti-osteoporo-
tic treatment. Treatment appropriateness was assessed
according to the most relevant and high impact recom-
mendations with clearly defined treatment algorithms in
Spain (the Spanish National Health System guide (2010)
[20], the General Practitioners’ Society (2007) [21] and
the General Directorate for Pharmacy and Medical Pro-
ducts of Madrid (2007) [22]), and to the recommenda-
tions of the National Osteoporosis Foundation (NOF,
2010) [23], and the International Osteoporosis Founda-
tion guidelines (IOF, 2008) [24].
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▪ Of the patients: age, sex, height and weight with a
body mass index calculation, smoking habits, consump-
tion of alcohol, exercise habits, antecedents of first
degree family member with hip fracture, low calcium
intake, non-treated hypogonadism, rheumatoid arthritis,
other diseases that decrease bone mass (excluding hypo-
gonadism), use of oral glucocorticoids, drugs that
decrease bone mass (excluding glucocorticoids), pre-
vious osteoporotic fracture, high risk of fall, prolonged
immobilization, osteoporosis of the lumbar spine
assessed by DXA (T score for L2-L4), osteoporosis of
the hip assessed by DXA for the whole hip or femur
neck (T score), concomitant medication and morbidity,
and mortality.
▪ Of the primary care doctor:a g e ,s e x ,t r a i n i n g
(whether she/he gained their Family Physician certificate
after a nationally accredited 3-4 year residency pro-
gram), work situation (fixed employment/other unde-
fined issues), time working in primary care (years), time
in current position (years), specialty.
▪ Of the Institution: Primary Healthcare Center, Basic
Healthcare Zone, and Health Department.
Data sources
The main source of data will be the ABUCASIS electro-
nic clinical records which, apart from clinical and socio-
demographic data about the patient, contain all the
information pertaining to the prescription and dispensa-
tion of drugs (electronic prescription system-GAIA) in
ambulatory care (primary and specialized care). To iden-
tify those patients who either die or move to other
Regions of Spain (censured cases); this data source will
be complemented by the Population Information System
of the Valencia Health Ministry.
Baseline data will be collected during the initial visit,
using a new modified version of the ABUCASIS specifically
developed to collect information about the variables used in
the study that were not routinely found in clinical records.
The results of previous examinations (x-rays or densitome-
try) that may have been performed on the patients will be
included in the initial evaluation (information about pre-
vious fractures and densitometry values). In the case of den-
sitometry results, the information that will be included in
the initial evaluation will be from examinations done in a
period of ± 2 years at the time of recruitment.
Statistical Analysis
1) Once the recruiting process has been completed, the
cohort baseline data will be analyzed. This will include
the description of the characteristics of the study sub-
jects, the treatments employed, and treatment appropri-
ateness. The appropriate parameters (means,
proportions) will be used with each variable with their
corresponding 95% confidence intervals (CI95%).
2) At the end of the follow-up period, a descriptive
analysis of compliance with and persistence of anti-
osteoporotic treatments will be carried out. This analysis
will also be stratified according to the degree of appro-
priateness and FRAX scales.
3) Next, Cox proportional hazards models will be used
to evaluate the independent factors associated with com-
pliance with and persistence of treatment.
4) Finally, a hierarchical analysis (multilevel) will be
carried out with respect to the appropriateness variable
on 4 levels: 1.) Clinical and demographic variables of the
patient, 2.) Doctor variables,3 . )V a r i a b l e so ft h eB a s i c
Healthcare Zone/Primary Healthcare Center and 4.)
Health Area.
The analyses will be carried out with the aid of the
STATA v. 10 and R statistical packages.
Ethical aspects
Interventions derived from the study
This observational study will be carried out under the
usual conditions of clinical practice and in accordance
with best clinical practices. No test or treatment derived
solely from this study (over and above a detailed medi-
cal history which will be collected as part of the usual
electronic medical records) will be carried out.
Compliance with the standards of good research practices
This study will be conducted in accordance with the
international standards for epidemiological studies, as
established in the International Guidelines for Ethical
Review of Epidemiological Studies (Council for the
International Organizations of Medical Sciences-
CIOMS-Geneva, 2009) and with the recommendations
of the Spanish Epidemiological Society on the review of
ethical issues in epidemiological research.
Committee for Ethics and Clinical Trials
This study shares all the aspects of data sources, data man-
agement, and confidentiality with the ESOSVAL-R study,
which has already been approved by the Committee for
Ethics and Clinical Trials of the Center for Public Health
Research and the Public Health Administration (CEIC
CSISP-DGSP). In addition, all the study subjects have
given their informed consent for access to anonymized
data in the databases containing their medical records.
Likewise, the participating centers have signed the corre-
sponding informed agreements concerning their collabora-
tion in the study. Nevertheless, in accordance with the
Resolution of the Regional Health Secretary dated Decem-
ber 15, 2009, with regard to the request for data, treatment
of data, and release of data from the ABUCASIS system
(SIA-GAIA), a request for any new variable in the ABU-
CASIS system requires separate and renewed approval by
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CEIC CSISP-DGSP.
Discussion
Like all observational studies, ESOSVAL-AD has several
limitations which we have tried to minimize. Those
most noteworthy include:
1. Selection bias
Although a certain degree of selection bias is inevitable
(the elderly and the very ill cannot physically get to the
Primary Healthcare Center as often as others), it is also
possible that collaborating researchers select study sub-
jects who are easier to interview (e.g. with a higher cul-
tural level) and avoid choosing other candidates. To
reduce this bias, we will highlight its importance in our
training sessions and we have also prepared a selection
scheme based on surgery timetabling and the scheduling
of the patients.
2. Information bias due to the absence of registry or
differential of registry of data in the electronic clinical
records
Although this problem is ever present when a study is
based on data from real clinical practices, various strate-
gies will be applied to minimize its effect: a.) To guaran-
tee that all the participating clinicians are up to date on
the topic of osteoporosis, that during medical visits they
all respond in a similar fashion and that the quality of the
electronic clinical records is as high as possible, all the
participating clinicians (800) will take part in a 300-hour
training course, both in-class and on line, on the manage-
ment of osteoporosis patients. The course is to be offered
through the Valencia School of Health Studies and accre-
dited by the National Health Service; b.) The electronic
clinical records system has also been modified to improve
data collection and unify the registry with regard to initial
visits as well as during follow up. These improvements in
the electronic medical records system apply to all health-
care professionals in the health system, and not only to
those participating in this study.
3. Intervention and maturation bias
Due to the training sessions associated with the ESOS-
VAL project as well as to the fact that in an open study
clinicians undergo a learning process, patients included
in this study may be better monitored and receive more
treatment than the general population. This could lead
to differences not only in the prevalence of anti-osteo-
porotic treatments, but also in treatment appropriate-
ness and adherence between cohort participants and the
p o p u l a t i o na saw h o l e .T h i sp o s s i b l eb i a si sp r e s e n ti n
all open studies and is difficult to handle. In our case,
given that the educational input is concentrated at the
beginning of the study, we are hopeful that the impact
of this bias will be minimized.
4. Measuring compliance
The assessment of compliance has been carried out
with the aid of the electronic prescription system
(GAIA) of the Valencia Health Ministry. Although this
is a reliable system for evaluating compliance in terms
of counting pills (number of pills dispensed/number of
pills necessary for treatment in the evaluation period),
it is not possible to know for certain whether the
patient has actually taken the medicine in the pre-
scribed dose and manner and is following the doctor’s
recommendations.
5. Anti-osteoporotic treatments
the information regarding medicines dispensed will be
taken from the electronic prescription system (GAIA)
included in ABUCASIS. This system only contains infor-
mation from ambulatory care; therefore we don’th a v e
information about medicines dispensed in hospitals. The
only drug affected by this limitation is zoledronic acid,
and therefore we will not have information about it in
this study.
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